Morepen Laboratories

Morepen Laboratories FCF Yield

The Free Cash Flow Yield of Morepen Laboratories (MOREPENLAB.NS) as of Oct 23, 2026 is -8.62 %. In the previous year, Free Cash Flow Yield was -0.38 % — a change of 2,188.43% (lower).

FCF Yield

-8.62 %

YoY

2,188.43%

Last updated:

Free Cash Flow Yield of Morepen Laboratories is 2025 -8.62 % . Free Cash Flow Yield of Morepen Laboratories was 2024 -0.38 % . It decreases by 2,188.43% lower compared to the previous year.

The Morepen Laboratories FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
1.73 INR
Jan 1, 2019
0.26 INR
Jan 1, 2020
-0.29 INR
Jan 1, 2021
0.49 INR
Jan 1, 2022
-5.92 INR
Jan 1, 2023
-6.49 INR
Jan 1, 2024
-0.38 INR
Jan 1, 2025
-8.62 INR
The Morepen Laboratories FCF Yield history
YEARFCF YieldYoY
-8.62 %+2,188.43%
-0.38 %-94.20%
-6.49 %+9.60%
-5.92 %-1,299.98%
0.49 %-272.36%
-0.29 %-209.35%
0.26 %-84.86%
1.73 %+18.33%
1.46 %-23.07%
1.90 %-12.50%
2.17 %+58.11%
1.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Morepen Laboratories Stock analysis

What does Morepen Laboratories do? Morepen Laboratories Ltd. generates revenue through the manufacturing and marketing of bulk drugs, pharmaceutical formulations, and home health products. The company produces active pharmaceutical ingredients (APIs) such as Apixaban, Edoxaban, Sitagliptin, and Rivaroxaban, which are sold to other pharmaceutical manufacturers. Its finished formulations, including Intebact Capsules, Intelicaps Lax, and Rythmix Kid Syrup, are marketed under its own brand for direct consumer sales. Home health products like the Dr. Morepen 49W Room Air Purifier and Dr. Morepen VP06 Breathe Free Vaporizer are sold directly to consumers through retail channels. The company's subsidiaries, Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited, support these product lines by handling specific manufacturing and distribution tasks. The primary customers for APIs are pharmaceutical companies seeking bulk ingredients for their own formulations. Finished formulations target healthcare consumers and pharmacies, while home health products are sold to households and medical facilities. The company's product segments are clearly divided: APIs for industrial clients, branded formulations for retail consumers, and home health devices for personal use. This segmentation allows Morepen to serve multiple market segments without overlapping product lines. Morepen's revenue streams are diversified across three main areas: API sales to pharmaceutical manufacturers, direct-to-consumer sales of branded formulations, and retail sales of home health products. The company's subsidiaries play a key role in supporting each segment, with Dr. Morepen Limited handling branded formulations, Morepen Devices Limited managing home health devices, and Total Care Limited likely supporting broader healthcare services. This structure ensures that each product line is efficiently managed and marketed to its respective target audience. Morepen Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Morepen Laboratories stock

Free Cash Flow Yield of Morepen Laboratories is -8.62 % in 2025.

Free Cash Flow Yield of Morepen Laboratories changed from -0.38 % to -8.62 %, representing a 2,188.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Morepen Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Morepen Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Morepen Laboratories

All Key Metrics — Morepen Laboratories